Blackstone Life Sciences (BXLS) is the life sciences private investment strategy of Blackstone, the world's largest alternative asset manager. Launched in 2018, BXLS manages over $15 billion and focuses on late-stage clinical asset financing for pharmaceutical and medical device companies.

In 2024, BXLS launched Neurvati Neurosciences, a dedicated neuroscience portfolio company formed to identify, acquire, and develop promising mid-to-late-stage therapeutics for neurological and psychiatric disorders. Neurvati was formed to address the chronic underinvestment in neuroscience and focuses on assets with clear clinical data packages and regulatory pathways. BXLS also has a prior investment in Praxis Precision Medicine (CNS disorders). BXLS's $6.3B BXLS VI fund (2024) is the largest life sciences private fund ever raised. The firm works primarily through royalty financing, product co-development partnerships, and ownership of therapeutic assets.